Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Active, Not Recruiting

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) - CA209-370

Updated: 1 July, 2019   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.
Print this page CA209-370
Download Study Participant’s Guide

SELECT LANGUAGE

Trial Details

  • Phase 1/Phase 2

    Phase

  • Gender(s)

  • 18+

    Age Range

  • Active, Not Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: Group A Nivolumab
Drug: Nivolumab
Experimental: Group A Nivolumab + SOC maintenance therapy
Drug: Pemetrexed Drug: Nivolumab Drug: Bevacizumab
Active Comparator: Group A SOC maintenance therapy
Drug: Bevacizumab Drug: Pemetrexed
Other: Group B Best supportive care
Other: Best Supportive Care
Experimental: Group B Nivolumab
Drug: Nivolumab
Active Comparator: Group C Investigator's choice chemotherapy
Drug: Pemetrexed Drug: nab-Paclitaxel Drug: Paclitaxel Drug: Docetaxel Drug: Gemcitabine Drug: Carboplatin
Experimental: Group C Nivolumb
Drug: Nivolumab
Active Comparator: Group D Erlotinib
Drug: Erlotinib
Experimental: Group D Nivolumab + Erlotinib
Drug: Nivolumab Drug: Erlotinib
Experimental: Group E Nivolumab + Crizotinib
Drug: Nivolumab Drug: Crizotinib

Key Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologically confirmed locally advanced or stage IV NSCLC - Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2 - Tumor tissue sections must be available for biomarker evaluation Exclusion Criteria: - Untreated or active/progressing Central Nervous system (CNS) metastases - Active, known or suspected autoimmune disease - Known history of testing positive for HIV or AIDS - Active or chronic infection of hepatitis B virus or hepatitis C

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com